钆塞酸二钠增强MRI定量评估肝纤维化的价值

目的:通过定量分析肝脏钆塞酸二钠增强MRI相对信号强度评估其对肝纤维化分级的价值。方法:回顾性分析2018年1月至2020年10月于河南省人民医院行钆塞酸二钠增强MRI并有肝脏组织病理学结果的131例患者的资料。根据肝纤维化Laennec分级系统对肝纤维化进行分级,F0~F1级27例、F2级19例、F3级17例、F4级...     

钆塞酸二钠MR成像联合APRI在慢性乙型肝炎肝纤维化的诊断价值

目的 探讨钆塞酸二钠MR成像联合APRI在慢性乙型肝炎肝纤维化的诊断价值。方法 选取行3.0T MR检查并证实肝纤维化Scheuer-Ludwig分期的慢性乙型肝炎患者92例,其中S1期25例、S2期18例、S3期22例、S4期27例。所有患者均行MR平扫及钆塞酸二钠增强扫描,测量平扫及增强后20 min肝胆期肝实质的信号强度(SI)值,计算肝胆期肝实质的对比增强指数(CEIHBP),并根据临床资料计算APRI。使用Mann-whitney U比较≥S2期(S1 vs S2-4)、≥S3期(S1-2 vs S3-4)、S4期(S1-3 vs S4)肝纤维化的CEIHBP、APRI及二者联合指标值,使用ROC曲线计算曲线下面积(AUC),评估CEIHBP、APRI及二者联合指标诊断不同肝纤维化分期的诊断效能。结果 CEIHBP、APRI及二者联合指标在≥S2期、≥S3期、S4期肝纤维化的差异均有统计学意义,二者联合指标的AUC值在≥S2期、≥S3期、S4期肝纤维化均高于CEIHBP及APRI,分别为0.849(95%CI:0.760～0.915)、0.835(95%CI:0.743～0....     

T1rho值对四氯化碳模型大鼠肝纤维化演变过程及严重程度的评估价值

目的探讨肝脏旋转坐标系下的自旋晶格弛豫时间(T1rho)值在四氯化碳(CCl4)建模大鼠肝纤维化进展及转归过程中的变化及对肝纤维化分期的价值。方法选取80只Sprague-Dawley大鼠采用随机数字表法分为3组,分别为CCl4组49只、恢复组20只、对照组11只,将大鼠分别标记行MRI基线扫描。CCl4组及恢复组大鼠经颈背部皮下注射CCl4进行建模,CCl4组于注药后4、6、8、10、12周末分别进行黑血T1rho扫描;恢复组大鼠于注药后4、6周末进行黑血T1rho扫描,第6周末扫描结束后停止注药,停止注药后1、2、4、6周末分别进行扫描;对照组于相同时间点注射等量玉米油,并于注射后第4、6、8、10、12周末分别进行黑血T1rho扫描。测量所有大鼠肝脏T1rho值,观察各组大鼠肝脏T1rho值随时间的变化。采用独立样本t检验比较各组大鼠相邻时间点肝脏T1rho值的差异。将实验鼠分为无肝纤维化组(S0)、轻度肝纤维化组(S1、2)及中重度肝纤维化组(S3、4),采用Kruskal-Wallis H检验分析3组间T1rho值间的差异,用受试者操作特征(ROC)曲线评估T1rho值对不同程度肝纤维化的诊断效能,采用Spearman检验评估T1rho值与肝纤维化严重程度的相关性。结果59只大鼠完成了整个实验,其中CCl4组28只、恢复组20只、对照组11只。CCl4组大鼠肝脏T1rho值随着注药时间的延长逐渐增加,8周末达到最大值,随后8~12周逐渐下降,除4周末与6周末、10周末与12周末大鼠肝脏的T1rho值差异无统计学意义(P值分别为0.112、0.487),其他相邻两个时间点大鼠肝脏T1rho值差异均有统计学意义(P均<0.05);恢复组大鼠肝脏T1rho值随着注药时间的延长逐渐上升,停止CCl4注射后肝脏T1rho值逐渐下降,相邻两个时间点大鼠肝脏T1rho值差异均有统计学意义(P均<0.05);对照组大鼠相邻时间点肝脏T1rho值差异均无统计学意义(P均>0.05)。无肝纤维化组(S0)、轻度肝纤维化组(S1、2)及中重度肝纤维化组(S3、4)大鼠分别为15、23、21只,T1rho值分别为[36.3(34.4,41.4)]、(47.2±8.4)、(48.8±9.0)ms,大鼠肝脏T1rho值随着肝纤维化程度的加重而加重,二者呈低度正相关(r=0.402,P=0.001);上述3组大鼠肝脏T1rho值间差异有统计学意义(P<0.01)。肝脏T1rho值鉴别无肝纤维化(S0)与有肝纤维化(S1~4)的ROC下面积为0.825(95%可信区间0.720~0.931),鉴别无或轻度肝纤维化(S0~2)与中重度肝纤维化(S3、4)的ROC下面积为0.668(95%可信区间0.540~0.796)。结论T1rho值对评估CCl4建模大鼠肝纤维化进展及转归有一定意义,对鉴别是否存在肝纤维化诊断价值中等,对鉴别轻度肝纤维化与中重度肝纤维化诊断价值较低。     

肝脏原位注射新生大鼠肝细胞构建的工程化肝组织对大鼠肝纤维化的影响

目的观察原位注射新生大鼠肝细胞构建的工程化肝组织对实验性肝纤维化大鼠血清和肝组织学的影响,探讨其抗肝纤维化的作用。方法用四氯化碳制成实验性肝纤维化造模大鼠,肝脏原位多点注射工程化肝组织,3周后测定血清肝功能并行肝组织学检查。结果原位注射组大鼠肝功能较单纯假手术组大鼠有改善,且具有显著差异（P〈0．05）,HE染色提示纤维化明显改善。结论肝脏原位多点注射新生大鼠肝细胞的工程化肝组织能改善大鼠肝纤维化进程,有一定抗肝纤维化作用。     

钆塞酸二钠增强T1-mapping 成像和DWI对肝纤维化分期的评估价值

【摘要】目的：探讨钆塞酸二钠（Gd-EOB-DTPA）增强T1-mapping成像和DWI对肝纤维化分期的评估价值。方法：共99例被检者符合入组标准并纳入研究,其中对照组23例（健康志愿者,S0）,病例组76例。病例组中,慢性乙型肝炎肝纤维化S1期13例,S2期13例,S3期26例,S4期24例。采用Look-Locker序列于增强前及Gd-EOB-DTPA增强后20min（肝胆期）采集T1-mapping图像,并测量肝组织弛豫时间T1,同时计算肝胆期弛豫时间T1减低率（ΔT1）。进行DWI检查并测量肝脏ADC值。采用单因素方差分析比较不同组别ADC值、ΔT1及肝胆期弛豫时间T1（T1HBP）。应用ROC曲线分析ADC、T1HBP、ΔT1对肝纤维化≥S2期、≥S3期的诊断效能。采用Spearman相关分析评价各参数与肝纤维化分期的相关性。结果：S0组（对照组）的ADC、T1HBP、ΔT1分别为（1.57±0.16）×10-3mm2/s、( 239.08±20.63)ms、( 69.24±4.64)% ;S1组分别为( 1.44±0.12)×10-3mm2/s、(273.57±53.75)ms、( 64.27±9.94)% ;S2组分别为( 1.31±0.12)×10-3mm2/s、( 375.74±97.86)ms、(61.14±5.61)% ;S3组分别为( 1.18±0.09)×10-3mm2/s、( 561.59±56.55)ms、( 38.76±6.08)% ;S4组分别为( 1.03±0.08)×10-3mm2/s、( 564.69±68.62)ms、 ( 37.01±6.80)% 。S0、S1、S2、S3、S4组的ADC值、ΔT1 和T1HBP均具有统计学差异(P均＜0.05)。ADC值、ΔT1和T1HBP诊断肝纤维化≥S2期的曲线下面积（AUC）分别为0.903,0.987,0.984;诊断肝纤维化≥S3期的AUC分别是0.817,0.930,0.847。ADC值与肝纤维化分期呈负相关（r=－0.790,P=0.000）,T1HBP与肝纤维化分期呈正相关（r=0.822,P=0.000）,ΔT1与肝纤维化分期呈负相关（r=－0.832,P=0.000）。结论:Gd-EOB-DTPA增强T1-mapping成像和DWI对肝纤维化分期的评估具有一定的价值。     

T1ρ MR能敏感地评估肝纤维化:大鼠胆管结扎模型的实验研究

目的在大鼠模型中研究旋转坐标系测得的自旋-晶格弛豫时间(T1ρ)与肝纤维化程度的相关性。材料与方法实验设计方案与操作流程经本校动物实验伦理委员会批准。结扎胆管诱导肝纤维化建立动物模型。在3T临床MR设备上进行2项研究,相隔1个月。第1项研究在胆管结扎手术     

钆塞酸二钠增强MRI对肝功能的定量评估

目的探讨是否可以用钆塞酸二钠增强MRI来评估与吲哚菁绿(indocyaninegreen,ICG)清除相关的肝功能。材料与方法本回顾性研究获得伦理委员会批准,免除受试者知情同意。23例病人均进行了ICG清除试验和钆塞酸二钠增强MRI检查,且增强扫描前后MRI检查参数一致。注射钆     

肝内肿块型胆管癌的钆塞酸MRI强化模式

摘要目的评估肝内肿块型胆管癌(IMCC)钆塞酸MRI强化模式,重点评估肝胆管期。材料与方法本回顾性研究得到了机构审查委员会的批准,且无需病人的知情同意。2008年5月-2010年12月期间,50例IMCC病人(女41例,男9例;平均年龄62.3岁,     

使用MR对比剂后大鼠肾源性系统性纤维化模型中皮肤中钆的滞留

目的应用肾源性系统性纤维化动物模型,检测钆在皮肤滞留的超微结构位点,并比较线性、低稳定性钆螯合物(钆双胺配置)与大环型、高稳定性钆螯合物(Gd-DOTA配     

Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans of the rat liver

Purpose

The purpose of this study was to investigate the effect of lapatinib treatment on hepatic parenchymal enhancement on Gd-EOB-MRI scans in rat.

Materials and methods

Institutional animal review board approval was received prior to the commencement of all studies. Five rats received a single oral dose of 100 mg/kg/day lapatinib for 7 consecutive days. The controls (n = 5) were given 0.5 % (w/v) aqueous hydroxypropyl methyl cellulose containing 0.1 % (v/v) Tween 80 for 7 days. After the acquisition of gadoxetate disodium-enhanced MR images using 0.025 mmol gadolinium/kg, their livers were subjected to pathologic study to determine the expression level of organic anion-transporting polypeptide 1 (oatp1) and multi-drug resistance-associated protein 2 (mrp2).

Results

Relative enhancement of the liver was similar in both groups. At the hepatobiliary phase, which in rats occurs 3 min after the injection of Gd-EOB, it was 0.90 ± 0.06 in lapatinib-treated rats and 0.84 ± 0.08 in the controls (p = 0.30). There was also no difference in the expression level of oatp1 and mrp2.

Conclusion

In rats, the administration of lapatinib for 7 days had no effect on hepatic parenchymal enhancement on Gd-EOB-MRI scans.     

Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors

Purpose:

To identify factors influencing hepatobiliary phase (HBP) hepatic enhancement on gadoxetate disodium‐enhanced MRI in patients with chronic liver disease (CLD).

Materials and Methods:

We retrospectively reviewed abdominal gadoxetate disodium‐enhanced MRIs and medical records of patients with (n = 97) and without (n = 48) CLD. CLD subgroups were formed based on normal/abnormal components of liver function tests (LFTs). Hepatic enhancement coefficients (HEKs) were calculated on MRI, and compared with LFTs and Model for End‐stage Liver Disease (MELD) scores.

Results:

The mean HEK was significantly lower (P < 0.0008) in the CLD than control group. The mean HEK was similar to controls in the subgroup with all normal LFTs (P = 0.09) and subgroup with normal direct bilirubin (DB) (p = 0.09), while it was significantly reduced (P < 0.0001) in the subgroup with elevated DB. For all other LFT components, regardless of normal or abnormal values, there was a significant reduction in the mean HEKs versus controls (all P values <0.01). There was a highly negative correlation between the mean HEKs in CLD subgroups and number of abnormal LFTs (r = ?0.93) and MELD scores (r = ?0.89).

Conclusion:

HBP hepatic enhancement in CLD patients is similar to those with no CLD as long as direct bilirubin remains normal. Higher MELD scores and higher number of abnormal LFT components are associated with reduced hepatic enhancement. J. Magn. Reson. Imaging 2011;. © 2011 Wiley‐Liss, Inc.

     

Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study

Aims

To evaluate motion artifacts, breath-hold failure, acute transient dyspnea, and clinical parameters during hepatic arterial phase of gadoxetate disodium-enhanced magnetic resonance (MR) imaging.

Methods

This was an institutional review board-approved observational prospective study (written informed consent acquired) performed in 250 consecutive patients, who underwent liver MR with a multiarterial phase technique. Oxygen saturation (SatO₂) and heart rate (HR) were monitored, while patients reported subjective symptoms. Breath-holds were assessed using prospective acquisition correction technique (PACE) monitors. Three readers independently analyzed all images to establish the presence of motion artifacts. Nonparametric statistical testing and Fleiss’ kappa were used.

Results

No statistical differences in SatO₂ and HR values were observed during the entire length of MR examination. The PACE graphs showed an altered breath-hold in 16/250 patients (6.4%), however only 6 patients self-reported symptoms during the procedure, and among these 6 subjects, only 2 suffered from acute transient dyspnea (0.8%). Motion-related artifacts increased mostly in the third arterial phase of gadoxetate disodium acquisition (p?<?0.0001): The artifacts incidence was 2.9% in the first phase; 4.0% in the second; and 19.5% in the third. This increase was mainly due to patients’ inability to hold their breath for the entire duration of the examination. However, at least one gadoxetate disodium arterial phase without motion artifacts and adequate for acquisition timing, was acquired in all MR examinations.

Conclusion

The incidence of breath-hold failure and acute transient dyspnea after gadoxetate disodium administration increased during the third arterial phase only. Our protocol allowed the acquisition of at least one arterial phase not compromised by motion artifacts and adequate for acquisition timing, in all patients.

     

The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green

Objectives

To assess the inhibitory effect of gadoxetate disodium on the transporter system using indocyanine green (ICG).

Materials and Methods

Groups of six female B6 Albino mice were injected with the test agent (0.62 mmol/kg gadoxetate disodium) or phosphate-buffered saline (control) 10 min before injection of ICG. Identical fluorescence images were subsequently obtained to create time-efficiency curves of liver parenchymal uptake. The study was performed on hypothermic and normothermic mice. The logarithms of the absorption rate constants (logKa values) and of the elimination rate constants (logKe values) were calculated for each experimental condition, and between-group differences were compared using Student’s t-test.

Results

The logKe values of the test group were lower than those of the control group at both temperatures (-6.52 vs. -5.87 under hypothermic conditions and -4.54 vs. -4.14 under normothermic conditions), and both differences were statistically significant (p = 0.037, 0.015 respectively). In terms of the logKa values, although the difference did not reach statistical significance (p = 0.052), the test group had lower values than the control group under hypothermic conditions (-0.771 vs. -0.376). In normothermic mice, the logKa values for the test and control groups were 0.037 and 0.277 respectively, thus not significantly different (p = 0.404).

Conclusions

Gadoxetate disodium inhibited ICG excretion. Thus, gadoxetate disodium inhibited the ATP-binding cassette sub-family C member 2 transporter.

Key Points

? Gadoxetate disodium inhibited ICG excretion. ? Gadoxetate disodium tended to inhibit hepatic ICG uptake. ? Drug-drug interactions of gadoxetate disodium need further investigation.

     

肝脏MR动态增强扫描：Gd-EOB-DTPA与Gd-DTPA的个体内对照研究

目的：比较钆塞酸二钠（Gd-EOB-DTPA）及钆喷酸葡胺（Gd-DTPA）肝脏 MR动态增强扫描腹腔脏器及血管的强化特点,重点比较Gd-EOB-DTPA移行期与Gd-DTPA平衡期的图像特点。方法：本研究为前瞻性、个体内随机对照研究。25例病理证实为原发直肠癌或结肠癌、怀疑肝转移的患者,3天内行2次肝脏 MR 动态增强检查,分别使用 Gd-EOB-DTPA及Gd-DTPA两种对比剂。动态增强扫描的序列相同,包括平扫、动脉期、门静脉期、平衡期（Gd-DTPA）／移行期（Gd-EOB-DTPA）。图像客观评估中,测量各期相图像上血管及肝脾实质的信号强度。以椎旁肌肉的信号为参考,计算相对信号强度（RS）并比较两组间的差异,以及不同期相时肝实质RS的差异。主观评估：读片者主观评价增强扫描各期相图像上,主动脉、门静脉及肝静脉与肝实质的相对信号强度。结果：肝实质的RS：在动脉期Gd-DTPA 组明显高于Gd-EOB-DTPA组（t＝3．006,P＝0．005）;在门静脉期及平衡期／移行期,两组检查的差异无统计学意义（t＝1．788,P＝0．086;t＝0．781,P＝0．442）。Gd-EOB-DTPA检查时,门静脉期肝实质RS明显高于动脉期（t＝－3．014,P＝0．006）,移行期RS与门静脉期的差异无统计学意义。Gd-DTPA检查时,平衡期肝实质RS明显低于门静脉期（t＝5．827,P＝0．000）。主观评估：Gd-DTPA增强扫描平衡期图像上所有患者的主动脉、门静脉、肝静脉均为高信号（100％）;Gd-EOB-DTPA 增强扫描移行期图像上主动脉、门静脉、肝静脉均以低或等信号为主（84％,92％,92％）。结论：Gd-EOB-DTPA动态增强 MR 检查,肝脏实质在门静脉期及移行期呈持续强化,其移行期的图像特征与Gd-DTPA平衡期的图像特征有明显不同,在影像诊断时应予以关注。